10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
T-Cell Lymphomas
1 article
Valemetostat Shows Promise in Treating Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase 2 trial of valemetostat demonstrates high response rates in difficult-to-treat lymphoma patients.